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Loss of the homeostatic protein 
BPIFA1, leads to exacerbation of 
otitis media severity in the Junbo 
mouse model
Apoorva Mulay1, Derek W. Hood2, Debbie Williams2, Catherine Russell1, Steve D. M. Brown2, 
Lynne Bingle3, Michael Cheeseman4,5 & Colin D. Bingle  1,6
Otitis Media (OM) is characterized by epithelial abnormalities and defects in innate immunity in the 
middle ear (ME). Although, BPIFA1, a member of the BPI fold containing family of putative innate 
defence proteins is abundantly expressed by the ME epithelium and SNPs in Bpifa1 have been 
associated with OM susceptibility, its role in the ME is not well characterized. We investigated the role 
of BPIFA1 in protection of the ME and the development of OM using murine models. Loss of Bpifa1 did 
not lead to OM development. However, deletion of Bpifa1 in Evi1Jbo/+ mice, a model of chronic OM, 
caused significant exacerbation of OM severity, thickening of the ME mucosa and increased collagen 
deposition, without a significant increase in pro-inflammatory gene expression. Our data suggests that 
BPIFA1 is involved in maintaining homeostasis within the ME under steady state conditions and its loss 
in the presence of inflammation, exacerbates epithelial remodelling leading to more severe OM.
Otitis Media (OM), or middle ear (ME) inflammation, is the most prevalent paediatric disease and the leading 
cause of paediatric surgery, antibiotic prescription and conductive hearing impairment1. Acute OM is primarily 
caused by the normally commensal bacteria non-typeable Haemophilus influenzae (NTHi), Streptococcus pneu-
moniae and Moraxella catarrhalis2 while chronic forms of OM show a genetic component of 45–75%3. The large 
numbers of OM susceptibility genes that have been identified emphasize the importance of innate immunity in 
protection against OM development4–7. More than 20 mouse genetic models of chronic OM have been character-
ised in recent years and these have proven to be a powerful tool in understanding the pathobiology of OM (For 
review, see 8) One such model is the N-ethyl-N-nitrosourea (ENU) mutant mouse, Junbo, that spontaneously 
develops chronic suppurative Otitis media (CSOM) under specific pathogen free (SPF) conditions, characterised 
by development of cellular fluid and hypoxia in the ME and inflammatory thickening of the mucoperiosteum. The 
causative mutation is a SNP in the gene encoding the transcription factor EVI1, also known as MECOM8,9. EVI1 
is an inducible negative regulator of NFkB10 and a repressor of the TGFβ signalling pathway11. The heterozygous 
mutant Evi1Jbo/+ mouse has increased responsiveness to microorganisms and inflammatory stimuli10.
The ME is an anatomical extension of the upper respiratory tract (URT) and demonstrates similar physi-
ological and immune mechanisms. The epithelium of the URT and its secretions play a key role in protection 
against environmental insults and infections. BPIFA1, a member of the bacterial permeability-increasing (BPI) 
fold containing family of putative innate defence proteins, is one of the most abundant secretory proteins in the 
URT. Its expression is restricted to the nasal passages, oropharynx, trachea and bronchi12,13, where it localises 
to a non-goblet, non-ciliated population of secretory cells14, minor glands and mucous cells of the sub-mucosal 
glands13–15. Secreted BPIFA1 is found in nasal lavage, saliva, sputum and bronchoalveolar lavage (BAL)13 and in 
the apical surface lining (ASL) fluid from air liquid interface cultures of differentiated tracheobronchial epithelial 
cells16,17.
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Alterations of BPIFA1 levels are associated with multiple URT diseases such as cystic fibrosis18 and chronic 
rhinosinusitis19. Despite the lack of compelling mechanistic evidence to identify the precise biological function 
of BPIFA1, an increasing number of studies suggest that it plays a multifunctional host defence role in the con-
ductive airways16. In line with the structural similarity to BPI20, BPIFA1 exhibits antimicrobial activity against 
a variety of respiratory pathogens and deletion of Bpifa1 in mice is associated with increased susceptibility to 
pulmonary infections21–25. Other proposed functions of BPIFA1, include a surfactant-like activity, dispersal of 
bacterial biofilms, and regulation of ASL volume by modulation of epithelial sodium channel (ENaC) function16.
Recently, evidence of BPIFA1 expression in the ME and its involvement in OM pathogenesis has started to 
emerge. Knocking down Bpifa1 expression in vivo using siRNA in chinchillas led to impaired mucociliary clear-
ance23. BPIFA1 protein was present in the effusions of patients with chronic OM26,27 and BPIFA1 was also iden-
tified as one of the top hits in a Genome Wide Association Study of genes associated with OM susceptibility28. 
We recently showed production of BPIFA1 in the murine ME, in vivo and in vitro29 and it has been reported 
that Bpifa1−/− mice greater than 10 months-of-age show increased susceptibility to spontaneous development of 
chronic OM30. Together this data suggests that BPIFA1 may be a determinant for predisposition to OM.
In this study, we have studied the role that BPIFA1 plays in protection of the ME and its association with OM 
development. Our data shows that although the loss of BPIFA1 did not lead to the development of spontaneous 
OM in mice up to 6 months-of age, it significantly exacerbates the inflammatory phenotype in the Junbo model of 
chronic OM. Our data suggests that BPIFA1 is involved in maintaining homeostasis within the ME under steady 
state conditions. This is the first study to report the use of compound Bpifa1 mutants and it underlines the impor-
tance of investigating the additive effect of multiple genetic defects in order to better understand the aetiology of 
multifactorial diseases such as OM.
Results
BPIFA1 is localised to the middle ear epithelium from birth but loss of the protein is not associated 
with spontaneous or bacteria induced development of OM. We have previously reported significant 
production of BPIFA1 in the respiratory epithelium of the nasal passages and ME29,31. In order to evaluate the onset 
of BPIFA1 production during the post-natal development of the bulla, immunohistochemistry (IHC) was performed 
from the day of birth (P0) to P30 at intervals of 5 days. BPIFA1 was detected in the ME throughout this period. As 
described previously, between P0 to P10, the ME space is occupied by mesenchyme32. BPIFA1 was detected in the 
non-ciliated epithelium enclosing this mesenchyme mass, in the region where it retracted from the opposing epithelial 
surface (Fig. 1A,B). Regression of the mesenchyme began at P5, until an air filled cavity was formed by P15. BPIFA1 
was localised to the non-ciliated cells throughout the ME epithelium from P15 to P30 (Fig. 1C,D,E,G). The epithelium 
that lines the internal surface of the tympanic membrane (Tm) also stained positively for BPIFA1 (Fig. 1F).
Having established that BPIFA1 is present in the ME epithelium during the process of bulla cavitation, we went 
on to determine whether loss of the protein caused OM. Hearing thresholds, measured using broad-spectrum 
Auditory Brainstem Response (ABR) (which is indicative of conductive hearing loss), did not differ signifi-
cantly in Bpifa1−/− and Bpifa1+/− mice compared to WT mice at 8 (data not shown) or 12 weeks of age (Fig. 2A). 
Histological assessment of WT and Bpifa1−/− mice did not show signs of OM development, such as middle ear 
mucosal thickening or fluid build-up, at 12 weeks (Fig. 2B,C) or 6 months of age (Fig. 2D) (Sup Fig. 1). No mor-
phological differences were noted in the nasal passages, trachea or lung, (the primary sites of BPIFA1 expression) 
between WT and Bpifa1−/− mice up to 6 months of age (Sup Fig. 2) and no evidence of inflammatory disease was 
detected following a comprehensive screen of 42 tissues of Bpifa1−/− mice at 6 months of age (data not shown).
As the development of OM is often associated with bacterial infection, we investigated whether the loss of 
BPIFA1 modulated the ability of mice to respond to the intranasally (IN) inoculated otopathogen NTHi. The 
majority of ME bullae examined after culling the mice at day 3-post inoculation, were healthy, air-filled and had 
intact tympanic membranes. Only a small proportion of Bpifa1−/− (2/12) and Bpifa1+/− (2/8) bullae contained 
fluid and 2/12 Bpifa1−/− ears and 1/8 Bpifa1+/− ears were NTHi culture positive. WT bullae (n = 16 ears) did not 
have fluids and all were NTHi culture negative. Although this data was suggestive of an effect of loss of Bpifa1 
on infection these differences did not achieve statistical significance. A similar outcome was achieved when we 
challenged WT, Bpifa1+/− and Bpifa1−/− mice with NTHi using baroinoculation33,34 and sampled bulla fluids at 
day 3 post-inoculation (data not shown).
Taken together, the data suggested that deletion of Bpifa1 does not lead to spontaneous development of OM 
and does not lead to an increased ME infection or overt induction of OM following NTHi inoculation.
Evi1Jbo/+ mice show alterations of BPIFA1. As the loss of BPIFA1 did not result in spontaneous OM or 
increased susceptibility to ME infection following intranasal bacterial challenge we investigated how the pro-
tein might influence OM disease progression in an established model of OM, the Evi1Jbo/+ mouse. OM initiates 
spontaneously in Evi1Jbo/+ mice from P21 onwards and is characterised by significant remodelling of the middle 
ear epithelium9. At P28, IHC staining for BPIFA1 appeared to be reduced in the ME epithelium of Evi1Jbo/+ mice 
compared to their age matched WT littermate controls (Fig. 3A,B) and continued to reduce with OM progression 
up to P56 (Sup Fig. 3). In WT mice there was strong staining throughout the middle ear epithelium whereas stain-
ing in the Evi1Jbo/+ mice was seen in fewer cells and on the epithelial surface (Fig. 3B). To confirm whether the 
reduction in the epithelial staining intensity of BPIFA1 in Evi1Jbo/+ bullae was a result of a difference in epithelial 
gene expression, we compared expression of Bpifa1 in freshly isolated ME mucosal cells (mMMCs) from WT and 
Evi1Jbo/+ mice using RT-qPCR. This analysis showed that there was a significant down-regulation of Bpifa1 mRNA 
in Evi1Jbo/+ mMMCs when compared to WTs (Fig. 3C). However, BPIFA1 was clearly seen in the inflammatory 
ear exudates in histology sections of Evi1Jbo/+ mice by IHC (Fig. 3B) and by western blotting of Evi1Jbo/+ bulla fluid 
(Fig. 3D). The lack of middle ear fluid in WT mice precluded analysis of the secreted protein in these animals.
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Loss of Bpifa1 leads to an exacerbation of OM severity in P28 Evi1Jbo/+ mice. Next we tested if 
loss of BPIFA1 altered the prevalence or severity of OM in the Evi1Jbo/+ mouse. To do this we backcrossed the 
Bpifa1−/− mice onto the same background as the Evi1Jbo/+ mice, C3H/HeH. Analysis of the ME of P28 mice 
showed that histological OM was highly prevalent in both Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ mice as evidenced by 
microscopic thickening of ME mucosa and variable presence of bulla fluids and their cellularity (Fig. 4A–H). 
However, the proportion of Bpifa1−/−Evi1Jbo/+ ears that had grossly evident bulla fluids was significantly higher 
Figure 1. BPIFA1 is localised to the middle ear epithelium from birth. Low and high magnification images, 
representative of n = 3 mice showing IHC for BPIFA1 localisation in the non-ciliated epithelial cells of the 
developing ME cavity at P5 (A,B), P15 (C,D,E) and P30 (F,G). The mesenchyme which fills the post-natal ME 
cavity (A,B) is resorbed by P15 to form a fully air filled adult ME cavity (C).
www.nature.com/scientificreports/
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compared to Evi1Jbo/+ ears (Fig. 4I). Moreover, the percentage of Bpifa1−/−Evi1Jbo/+ with bilateral OM was signif-
icantly higher (p = 0.03) compared to Evi1Jbo/+ mice (Sup Fig. 4). Importantly, Bpifa1−/−Evi1Jbo/+ bullae showed 
significantly thickened mucosa compared to Evi1Jbo/+ ears (Fig. 3F). We looked for evidence of sub-epithelial 
fibrosis in inflamed Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ MEs by staining for collagen deposition (Fig. 5A–D) and the 
myofibroblast marker, α-Smooth Muscle Actin (α-SMA) (Fig. 4E–H). This qualitative analysis showed enhanced 
staining of both markers in the Bpifa1−/−Evi1Jbo/+ compared to both WT and the Bpifa1−/− mice. Thus, the data 
supported the observation that loss of Bpifa1 alone does not lead to spontaneous OM development in P28 mice 
but significantly exacerbates the OM phenotype in Evi1Jbo/+ mice.
Exacerbation of OM in Bpifa1−/−Evi1Jbo/+ mice is not due to an enhanced proinflammatory 
response, differentiation or proliferative response. As BPIFA1 has been suggested to exhibit an 
anti-inflammatory role we evaluated whether exacerbation of OM severity in Bpifa1−/−Evi1Jbo/+ mice resulted 
in an enhanced cytokine response. In order to test this, gene expression analysis for a selected panel of inflam-
matory markers was performed on RNA from freshly isolated mouse middle ear mucosal cells (mMMCs) 
from 7 to 10 week old Bpifa1−/−Evi1Jbo/+, Evi1Jbo/+, Bpifa1−/− and WT mice. Although mMMCs of Evi1Jbo/+ and 
Bpifa1−/−Evi1Jbo/+ mice had significantly elevated levels of the pro-inflammatory cytokines Cxcl2, Il1β, Tnfα and 
the profibrotic mediator, Tgfβ, compared to WT mMMCs, there was no significant difference in the expression 
levels for any of these genes between WT and Bpifa1−/− mMMCs or between Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ 
mMMCs (Sup Fig. 3A–D), suggesting that the loss of Bpifa1 did not modulate the cytokine response.
To evaluate if Bpifa1 loss on the Evi1Jbo/+ background led to an alteration in other epithelial cell types, we inves-
tigated expression of the secretory cell marker, Muc5ac, and the ciliated cell marker, Foxj1, in Bpifa1−/−Evi1Jbo/+, 
Evi1Jbo/+, Bpifa1−/− and WT mMMCs. Foxj1 was significantly down regulated in Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ 
mMMCs compared to WT mMMCs (Sup Fig. 5E). The difference in the level of expression of these markers 
between WT and Bpifa1−/− mMMCs and between Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ mice did not reach statisti-
cal significance (Sup Fig. 5E,F). This suggests that Evi1Jbo/+ mice show epithelial cellular alterations marked by 
down-regulation of Bpifa1 and Foxj1, but there is no significant additive effect of Bpifa1 deletion on expression of 
these epithelial cell type marker genes at this point. Muc5ac was significantly downregulated in Bpifa1−/−Evi1Jbo/+ 
mice compared to WT mice, but not in Evi1Jbo/+ mice, and there was also no significant difference between the 
levels of Muc5ac between Bpifa1−/−Evi1Jbo/+ and Evi1Jbo/+ mice (Sup Fig. 5F). Further evaluation using a larger 
number of mice may be necessary to unmask the potential effect of deletion of Bpifa1 on Muc5ac levels on the 
Evi1Jbo/+ background.
Figure 2. Loss of the BPIFA1 is not associated with hearing deficits or development of OM. Auditory brain 
stem thresholds for Bpifa1−/− (n = 13) and Bpifa1+/− (n = 18) mice do not differ significantly from those of WT 
mice (n = 9) at 12 weeks of age (A). p > 0.05 for One-way ANOVA with Tukey’s posthoc test. Representative 
High power images of H&E sections of the ME of n = 8 WT (B), and Bpifa1−/− (C) at 12 weeks age and n = 13 
Bpifa1−/− (D) mice at 6 months of age show no histological abnormalities. Scale bar 50 μm for 60x objective 
images.
www.nature.com/scientificreports/
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In order to investigate if the OM phenotype of the hyper-proliferative mucosa in Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ 
mice resulted in a cell-autonomous defect in the ME epithelium, we compared in vitro growth characteristics of 
mouse middle ear epithelial cells (mMECs) and fibroblasts isolated from the bullae of Bpifa1−/−Evi1Jbo/+, Evi1Jbo/+, 
Bpifa1−/− and WT mice. No significant differences in doubling times were seen in either mMECs (Sup Fig. 5G) 
or fibroblasts (Sup Fig. 5H) cultured from the 4 genotypes, indicating that the cells proliferated at similar rates 
in vitro. Thus, our data suggests that there is no cell-autonomous proliferative or differentiation defect in the 
Bpifa1−/−Evi1Jbo/+ cells that explains the differences observed in the ME in vivo.
Discussion
In this study we have explored the role of BPIFA1 in the context of ME host defence and OM. BPIFA1 is one of the 
most highly expressed proteins in the URT of humans and mice12,13, and forms a major component of secretions 
from these sites13,17. We have shown that the protein is present in the murine ME epithelium from birth. Bpifa1 
is expressed in the mouse nasal passages from e14.535,36 whereas expression in the mouse trachea begins around 
the time of birth36. Previous reports have shown presence of BPIFA1 in the ME of mice aged 10–18 months30. 
The abundant expression of BPIFA1 in the murine ME throughout the life span suggests a homeostatic role in 
protection of the ME epithelium and that its loss may play a role in the progression of OM.
However, our data shows that loss of Bpifa1 alone does not lead to the development of spontaneous OM in 
the mouse, up to 6 months of age. Although BPIFA1 is highly expressed in the nasal passages and trachea of WT 
mice, Bpifa1−/− mice did not exhibit any overt phenotypes in these regions either. In contrast an ENU Bpifa1−/− 
mutant, on a C3HeB/FeJ background, has been shown to develop low penetrance OM (30%) by 10–18 months 
of age30. This apparent difference could be due to strain differences (as we have studied mice on C57BL/6 J and 
C3H/HeH backgrounds) and could be further examined by studying our Bpifa1−/− model at a comparable age. 
However, OM is typically studied in young mice as this better represents the timing of the paediatric disease in 
humans9,28 and the relevance of any late development of the disease is unclear. As mice over expressing BPIFA1 
showed reduced levels of lung fibrosis when exposed to a sterile irritant37, it is possible that extended exposure to 
Figure 3. Analysis of BPIFA1 levels in the Evi1Jbo/+ middle ear. IHC analysis of P28 ME sections representative 
of n = 3 mice showing abundant staining of BPIFA1 along the WT ME epithelium (A) and reduction in staining 
intensity along Evi1Jbo/+ ME epithelium, but positive staining in the exudate (B). Arrows indicate positive 
staining; Scale bar: 500 μm for 4x objective images and 50 μm for 60x objective images (insets). RT-qPCR 
analysis of freshly isolated mouse ME mucosal epithelial cells (mMMCs) show a significant downregulation of 
Bpifa1 in Evi1Jbo/+ mucosa compared to WT mucosa. Data represented as individual RQ values ± SEM for three 
independent batches of freshly isolated mMMCs (each batch contains cells pooled from 6 mice). ***p < 0.001, 
2 tailed t-test (C). BPIFA1 is readily detected in the ME effusion of Evi1Jbo/+ mice by Western blot (D). Ear 
exudates from two different P105 and P59 animals showed presence of the full-length protein (25 kDa) along 
with partially degraded peptides. The control (BAL fluid from scgb1a1-scnn1b transgenic mice) showed presence 
of only the full-length protein.
www.nature.com/scientificreports/
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Figure 4. Exacerbation of otitis media severity in Bpifa1+/−Evi1Jbo/+ mice. Dorsal plane H&E sections 
from MEs of P28 WT (n = 28) (A,B) and Bpifa1−/− (n = 12) (C,D) mice show no otitis media development. 
Representative H&E sections from ME of P28 Evi1Jbo/+ (n = 34) (E,F) and Bpifa1−/−Evi1Jbo/+ (n = 32) (G,H) 
mice demonstrate presence of an OM phenotype characterised by mucosal thickening and the presence of 
inflammatory ear fluids (marked by star). Mucosa of Bpifa1−/−Evi1Jbo/+ (G,H) appears thicker than Evi1Jbo/+ 
mice (E, F). Scale bar 500 μm for low magnification images and 100 μm for high magnification images. High 
power images show overlays used to quantitate epithelial thickness. The percentage of MEs with grossly evident 
fluids (Fishers exact test) (I) and the mean mucosal thickness (One-way ANOVA with Tukeys post hoc test) 
(J) for Bpifa1−/−Evi1Jbo/+ was significantly higher compared to Evi1Jbo/+, WT and Bpifa1−/− mice; *p < 0.05; 
**p < 0.01; ****p < 0.0001.
www.nature.com/scientificreports/
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respiratory irritants or previous episodes of bacterial infection may be contributory to the low penetrance OM in 
aged Bpifa1−/− mice30.
The loss of bpifa1 has previously been shown to predispose mice more severe respiratory infections following 
an experimental challenge and yet we found that IN challenge of Bpifa1−/− mice with the major otopathogen 
NTHi, did not result in significant ME infection, although our data did appear to suggest that Bpifa1−/− mice 
infection prevalence was marginally higher. NTHi is a significant causative pathogen isolated from a majority of 
AOM and COME patients38 and the potential role that BPIFA1 plays in defence against this organism requires 
further studies.
Figure 5. Sub-epithelial fibrosis in Bpifa1−/−Evi1Jbo/+ and Evi1Jbo/+ middle ears. Picrosirius red staining showing 
collagen fibres in the sub-epithelial connective tissue of WT (A) and Bpifa1−/− (B) ME. Staining intensity 
increases in the inflamed and expanded mesenchyme of Evi1Jbo/+ (C) and Bpifa1−/−Evi1Jbo/+ (D) ME indicating 
increased deposition of collagen fibres. IHC analysis of ME sections shows no α-SMA staining in the thin sub-
epithelial mesenchyme of WT (E) and Bpifa1−/− (F) ME epithelium but intense α-SMA staining in the lower 
half of the expanded mesenchyme of Evi1Jbo/+ (G) and Bpifa1−/−Evi1Jbo/+ (H) ME. Arrowheads indicate positive 
staining. Data is representative of n = 3 mice for all genotypes. Scale bar: 500 μm for 4x objective images and 50 
μm for 60x objective images (insets).
www.nature.com/scientificreports/
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Given the high levels of BPIFA1 seen in the ME, but the absence of spontaneous OM or lack of significantly 
increased susceptibility to ME infection by NTHi in our Bpifa1−/− mice, we investigated the contribution of the 
protein to OM disease progression by studying compound mutant Bpifa1−/−Evi1Jbo/+ mice. Evi1Jbo/+ mice repre-
sent an established model of OM9,39 and develop hallmarks of the disease soon after middle ear cavitation occurs. 
Our analysis suggests that BPIFA1 protein staining was reduced in the remodelled epithelium in Evi1Jbo/+ mice 
compared to WT. It seems possible that this loss of staining may be due to an alteration of cell populations in the 
mucosa, with a reduction in the number of BPIFA1 producing cells being present. However we could still readily 
detect the protein in the ME exudates from Evi1Jbo/+ mice. This is consistent with proteomic data from human ME 
exudates26,27 and our own data from the apical secretions of differentiated mMECs29.
The most striking observation from these studies is that Bpifa1−/−Evi1Jbo/+ bullae demonstrated an exacer-
bation of OM severity compared to Evi1Jbo/+ mice. This suggests that removal of BPIFA1 from the middle ear 
environment allows for a more significant remodelling response. This further suggests a shifting of the time 
required to produce the OM phenotype. Indeed analysis of compound mutant mice at day P21 also revealed 
an exacerbation of OM severity (results not shown). It seems likely that the loss of BPIFA1 from the middle ear 
mucosa during the process of cavitation directly exacerbates the development of OM. Previous studies of Evi1Jbo/+ 
bulla exudates demonstrated elevation of inflammatory gene networks and hypoxia signalling genes compared 
to venous blood as a baseline control39. We have shown up-regulation of the pro-inflammatory mediators Cxcl2, 
Tnfα, Il1β and Tgfβ in the ME mucosa of Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ mice. Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ 
bullae also appeared to demonstrate epithelial cellular alterations characterised by down regulation of the cili-
ated cell marker, Foxj1, and the secretory cell marker, Muc5ac, and Evi1Jbo/+ mice demonstrated reduced levels 
of Bpifa1 expression. However, despite the exacerbated OM phenotype in Bpifa1−/−Evi1Jbo/+ mice, there was no 
significant additive effect of the loss of Bpifa1 on the expression of these inflammatory and epithelial markers. 
This may be a consequence of comparison based on the already inflamed Evi1Jbo/+ epithelium that has high basal 
expression levels of these inflammatory genes. At this time we are unable to identify exactly which cell type(s) 
express these pro-inflammatory markers but our mucosal cell isolation procedure generates a population of struc-
tural (epithelial and mesenchymal) cells without a significant inflammatory cell component.
The differences in the mucosal thickening of Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ mice do not appear to be 
explained by proliferation rates of the epithelial cells and fibroblasts measured ex-vivo. It seems likely that 
inflammatory changes such as connective tissue oedema, dilation of lymphatics and blood vessels, infiltration of 
inflammatory cells and fibrosis are responsible for the mucosal thickening seen in the ME. An interesting feature 
observed in the inflamed Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ MEs was fibrosis of the sub-epithelial connective tissue, 
indicated by collagen deposition and accumulation of myofibroblasts. These features are characteristic of fibrotic 
pulmonary diseases such as asthma and idiopathic pulmonary fibrosis40 and indicative of epithelial remodelling 
due to an over-active wound repair response following inflammation. In turn this is suggestive of over-activation 
of the TGFβ signalling pathway (a target for EVI1)41. The enhanced thickness of the Bpifa1−/−Evi1Jbo/+ mucosa 
compared to that of Evi1Jbo/+ mice suggests greater fibrosis due to loss of BPIFA1. BPIFA1 has been previously 
associated with an allergen-induced asthma-like phenotype in mice42 and overexpression of BPIFA1 has been 
shown to protect against pulmonary fibrosis37. A recent report suggesting a role for BPIFA1 as an epithelial 
derived smooth muscle relaxing factor43 is supportive of a potential role for this epithelial protein in mediating 
crosstalk with the underlying connective tissue.
An important observation in this study was the downregulation of epithelial Bpifa1 in the inflamed microen-
vironment of the Evi1Jbo/+ ears. This reduction in BPIFA1 may represent transcriptional down regulation of 
Bpifa1 or perhaps more likely is a consequence of phenotypic changes in the epithelial cell populations. Previous 
work with BPIFA1 has largely focused on evaluation of a role for the protein in bacterial and viral pathogen 
challenge studies or in the presence of pre-existing chronic allergic and inflammatory pulmonary disease (for 
review see16). Importantly, we did not observe any phenotypic abnormalities or signs of organ inflammation in 
the non-challenged Bpifa1−/− mice. Thus, the presence of an infectious or inflammatory stimulus seems to be a 
pre-requisite to uncover functional roles of BPIFA1. This may also explain why Bpifa1 deletion alone does not 
lead to the spontaneous development of OM in Bpifa1−/− mice. Consistent with this hypothesis we have recently 
shown that Bpifa1−/− mice are more susceptible to influenza A infection through a mechanism that allows Bpifa1 
deficient cells to be more readily infected by the virus44.
This work provides new insights into the function of BPIFA1 in the ME. From birth onwards BPIFA1 is 
secreted at high levels into a film that overlies the epithelium lining the ME, but its absence does not predispose 
to spontaneous OM or increase the susceptibility to bacterial infection. This indicates that, within normal limits, 
BPIFA1 is a functionally redundant innate immune protein that plays a homeostatic role in mucosal protection 
in a manner described for multiple respiratory proteins45,46. Further studies are required to address this point 
and whether the mechanism(s) are via alteration in surfactant function, epithelial permeability, and/or impaired 
antimicrobial action.
We have explored the role of BPIFA1 in mice bearing an OM predisposing Evi1 mutation, and shown an 
upregulation of ME epithelial cytokine expression and down-regulation of epithelial markers, with dispersal of 
BPIFA1 from this surface layer into bulla fluid. Deficiency of BPIFA1 on an Evi1 mutant background does not 
markedly alter epithelial cytokine and cell marker expression probably via perturbation of epithelial cell popula-
tions, and consequently exacerbates inflammatory thickening of the submucosal connective tissues.
Together this suggests that BPIFA1 aids homeostasis in the ME by contributing to the epithelial barrier func-
tion, and its role is revealed only under significant epithelial insult. Future time course studies are needed to 
define whether the deletion of Bpifa1 on an OM prone background results in the earlier initiation of OM and 
whether, once initiated, the progression of disease is significantly altered. It is also important to study if loss of 
BPIFA1 exacerbates the OM phenotype in other OM mutant mouse lines. Given that features such as mucosal 
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fibrosis have been noted in chronic OM in Tlr4 and Evi1 mutant mice9,47, early fibrosis, and mucosal thickening 
may suggest accelerated disease in the absence of BPIFA1 rather than substantially altered pathogenesis.
Materials and Methods
Ethics statement. Mice were bred and maintained by the Mary Lyon Centre, MRC Harwell and were 
housed in specific-pathogen free conditions. All animal experimentation was approved by the Animal Welfare 
and Ethical Review Body at MRC Harwell. The humane care and use of mice in this study was under the authority 
of the appropriate UK Home Office Project License.
Mice and husbandry. Bpifa1−/− mice on a C57BL/6 background were obtained from Professor Ralph Shohet 
at the University of Hawaii. The generation of these mice in which exons 2 and 3 of the Bpifa1 gene have been 
deleted have been described in detail elsewhere44. C57BL/6 Bpifa1−/− mice were re-derived at MRC Harwell 
Institute, UK and backcrossed 5 times to C3H/HeH mice to produce a congenic background. Junbo heterozygote 
(Evi1Jbo/+) mice were maintained on the C3H/HeH background9. Compound Bpifa1−/−Evi1Jbo/+ mutants and their 
littermate controls were generated by intercrossing Bpifa1−/− and Evi1Jbo/+ mice and mice were examined at P28 
and at 6 months of age. P0-P30 WT C3H/HeH mice, used for IHC of BPIFA1, were obtained from MRC Harwell 
Institute. For comparative purposes Bpifa1−/− mice on the original C57BL/6 background and a mixed C3H/
HeH-C57BL/6 background were used in some infection studies. Husbandry of SPF mice and microbiological 
surveillance is described elsewhere9.
Auditory Brainstem Response (ABR) measurement. The hearing thresholds of 8 and 12 week-old 
mice were assessed using ABR measurements as previously described9.
Tympanic membrane assessment. Mice were euthanized by intraperitoneal overdose of sodium pento-
barbital (Pentoject Animalcare, UK). The mouse was decapitated and head skin removed. The tympanic mem-
brane was examined under 10× binocular magnification to establish whether there was evidence of opacity which 
is indicative of macroscopic bulla fluid accumulation.
Histology. Tissue samples were fixed in 10% formaldehyde (Surgipath Europe) for 48 hours at room temper-
ature and the skulls decalcified in Kristenson D.F.B agent (Pioneer Scientific) for 72 hours before wax embedding. 
Four µm H&E stained sections of the bullae and nasal passages were scanned using the NanoZoomer Digital 
Pathology system and morphometric measurements made with NanoZoomer software (Hamamatsu). Thickness 
of the ME mucosa was measured in a defined 1 mm area in the promontory region opposite the tympanic mem-
brane. Average mucosal thickness was calculated using 5 measurements taken at a distance of 250 μm within this 
region. Both male and female mice were analysed and no sex-related differences were seen in the development of 
OM. H&E slides for sections of a total of 42 target tissues from Bpifa1−/− mice at 6 months of age were analysed 
for morphological abnormalities.
Immunohistochemistry. Four µm wax sections were used for IHC. Endogenous peroxidase activity was 
blocked using 0.3% hydrogen peroxide in methanol (Fischer Scientific, UK). Non-specific binding was blocked 
by incubating the sections in 100% goat serum for 30 minutes at room temperature. Sections were washed and 
incubated in rabbit anti-Bpifa1 (1:750)31 or rabbit anti-αSMA (1:200) (Abcam 5694) antibodies overnight in a 
humified chamber at 4 °C then washed twice in PBS, incubated in 0.5% biotinylated polyclonal goat anti-rabbit 
secondary antibody (VectastainR EliteR ABC kit, Cat No- PK-6101) for 30 minutes at room temperature, fol-
lowed by incubation for 30 minutes with the ABC reagent for signal amplification before colour detection using a 
NovaRed system (Vector, Cat No- SK 4800). Images were captured with an Olympus BX61 light microscope and 
Olympus colour view digital camera.
Preparation of NTHI bacterial inoculum and intranasal inoculation. Intranasal bacterial challenge 
experiments, using genomically sequenced, streptomycin resistant strain NTHi #375 (NTHi375SR), was per-
formed as previously described48.
Intranasal inoculation of mice using a barochamber. The baroinoculation protocol was adapted from 
previously published studies in mice33 and rats34. For baroinoculation, mice were first anaesthetised with isoflu-
rane then intranasally inoculated with 5 μl of 1 × 1010 CFU/ml NTHi into each nostril and placed in a pressure 
chamber (Scientific workshop, MRC Harwell Institute). The pressure was raised to approximately 1.4 pounds per 
square inch (Psi) by compressed air through an inlet port. Thereafter, the pressure was increased by approximately 
0.7 Psi every 15 secs to achieve a maximum pressure of 5.8 Psi, then after 2 minutes was decreased by venting air 
via an outlet port at 30 secs intervals to return the chamber to atmospheric pressure.
Middle ear cell isolation and culture. The isolation of mMECs was performed as previously described29. 
Fibroblasts were isolated using a differential adherence method described in the same paper. Adherent fibroblasts 
were cultured by adding 5 ml of mMEC basic 10% FBS media to the tissue culture dish29 and incubating at 37 °C 
in a 5% CO2 incubator till confluent. Upon confluence, cells were washed with warm HBSS and sub-cultured 
twice to obtain a pure fibroblast population. For the third passage, 3mls of Trypsin-EDTA solution (Sigma) was 
added to the dish and incubated as above for a minute to dislodge the cells. Trypsin was neutralised by addition 
of 3 ml neutralising medium (mMEC basic plus 10% FBS) and cells were centrifuged at 500 × g for 5 minutes. Cell 
pellets were resuspended in 5 mls of fresh mMEC basic 10% FBS and split into five T25 flasks for expansion of the 
fibroblast cultures. 4 ml of media was added to each flask and cells were cultured at 37 °C in 5% CO2 till conflu-
ence. When calculating population doubling time (PD), the purified fibroblasts were seeded at 5 × 104 cells/well 
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in mMEC basic 10% FBS media in 6 well tissue culture plates (Falcon). Similarly, fresh mMECs were seeded at 
5 × 104 cells/well in mMEC- Plus media29 in submerged culture. Media was changed every 48 hours. Fibroblasts 
were harvested every 24 hours from day1 to day 3 whereas mMECs were harvested every 48 hours by trypsinisa-
tion and quantified using a haemocytometer from day 2 to day 10.
Population doubling time was calculated using the formula.
PD T Log
Log C Log C
2
2 1 (1)
=
×
−
where, PD = Population doubling, T = time (24 hours for fibroblasts and 48 hours for mMECs), Log = Log10, 
C1 = initial cell count, C2 = final cell count.
Western Blotting. Bulla fluids were sampled by pipetting as previously described48, these were then mixed 
with an equal volume of 2XSDS lysis buffer. Samples were denatured at 95 °C for 5 minutes and resolved on a 
12% polyacrylamide gel, transferred to a PVDF membrane using a semi dry blotting system (Biorad Trans-blot 
turbo) then probed with rabbit anti-Bpifa1 primary antibody (1:20031), overnight at 4 °C. The primary antibody 
was detected using a polyclonal goat anti-rabbit secondary antibody (Dako P0448) conjugated with HRP (1:2000) 
and bound antibody was visualised using the EZ-Chemiluminescence detection system (Geneflow, Cat No- 
30500500B) and manual development. Images were scanned as a whole with no modification.
Real time quantitative PCR (RT-qPCR). For comparison of gene expression between WT, Bpifa1−/−, 
Evi1Jbo/+ and Bpifa1−/−Evi1Jbo/+ MEs, mouse mucosal epithelial cells (mMMCs), i.e. ME epithelial cells before 
undergoing the differential fibroblast separation, were used. Total RNA was extracted, cleaned from residual 
genomic DNA contamination, quantified and reverse transcribed into cDNA as previously described29. RT-qPCR 
was performed using Applied Biosystems TaqMan gene expression assays for Cxcl2 (Mm00436450_m1), TNFα 
(Mm99999068_m1), TGFβ (Mm01178820_m1), Bpifa1 (Mm00465064_m1), FoxJ1 (Mm01267279_m1) and 
Muc5ac (Mm01276718_m1) on a 7500 Fast Real Time PCR system (Applied Biosystems), with 2× Taqman Fast 
Universal Master Mix (Applied Biosystems, Cat No- 4352042). 10 ng cDNA was added to each reaction and three 
technical replicates were performed for each assay in each batch. Target gene expression levels were normalized 
to three endogenous controls: Atp5b, Cyc1 and Canx (Primerdesign geNormTM Reference Gene Selection Kit) and 
analysed using ABI 7500 software v2.0.1 using the 2−∆∆Ct method. Data is presented as mean Relative quantifica-
tion (RQ) and error bars represent standard error of the mean.
Statistics. The normality of experimental data was determined by performing Levene’s test prior to the sta-
tistical analysis. GraphPad Prism (version 6.0) was used to perform all statistical tests. 2 tailed students t-test was 
used to compare two groups of data. One way or two-way analysis of variance (ANOVA) with Tukey’s post hoc 
test was used to compare more than two groups, for parametric data. Fisher’s exact test was used for analysing 
frequency data such as presence or absence of bulla fluids or genotype ratios (Chi squared analysis was used 
if there were more than 3 groups). Significance threshold was set at p < 0.05. Data are presented as the mean 
+/− standard error of the mean (SEM) unless otherwise stated. Significance levels represented on graphs are as 
follows: ns = not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.
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